title: [Risk factors associated, diagnostic methods and treatment for endometriosis, used in clinical service endometriosis gynecology Hospital General de Mexico (2009-2011)].
abstract: BACKGROUND
  Endometriosis no ectopic endometrial stroma and glands. Have different risk factors. Four theories explain it: the theory of coelomic metaplasia, embryonic cell debris, deployment and immunological. Clinical data are pain and infertility. For the American Fertility Society (AFS) is divided into minimal, mild, moderate and severe. Diagnostic studies are antigen Ca 125, Magnetic Resonance, and abdominal ultrasound. The ideal method is direct visualization with histological confirmation. The medical and surgical treatment.
  
  
  OBJECTIVE
  To determine the risk factors, diagnosis of Endometriosis and effectiveness of treatments used in clinical Endometriosis Gynecology Unit at the General Hospital of Mexico OD.
  
  
  METHODS
  A descriptive, longitudinal and retrospective duration of 2 years 6 months in 30 patients diagnosed with endometriosis in the clinical treatment of Endometriosis General Hospital of Mexico OD.
  
  
  RESULTS
  The most affected age group was 21 to 25 years, the risk factors are Gesta 1, a resident of Mexico, Mullerian malformation. The symptom was dysmenorrhea. In 16 were diagnosed as a surgical finding and laparoscopically diagnosed.
  
  
  CONCLUSIONS
  It is important to study the risk factors. The diagnosis is made using clinical data, quantification of CA125 antigen and imaging studies. Medical treatment is indicated both in the preoperative as well as postoperative surgical treatment and seeks to eradicate the lesions.
authors.affiliation: Hospital General de México OD, México, DF.
authors.forename: Antonio
authors.initials: A
authors.lastname: Guerrero Hernández
authors.forename: Guillermo
authors.initials: G
authors.lastname: Oropeza Rechy
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Gómez García
mesh_terms: D000293:Adolescent; D000328:Adult; D018394:CA-125 Antigen / Q000097:blood; D015897:Comorbidity; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use; D003613:Danazol / Q000627:therapeutic use; D003952:Diagnostic Imaging / Q000379:methods; D004715:Endometriosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery; D005260:Female; D005833:Genital Neoplasms, Female / Q000453:epidemiology; D017273:Goserelin / Q000627:therapeutic use; D013509:Gynecologic Surgical Procedures / Q000706:statistics & numerical data; D058869:Gynecological Examination; D006769:Hospitals, General; D006801:Humans; D008800:Mexico; D008875:Middle Aged; D009775:Obstetrics and Gynecology Department, Hospital; D017584:Reproductive History; D012189:Retrospective Studies; D012307:Risk Factors; D055815:Young Adult
chemical_list: D018394:CA-125 Antigen; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D017273:Goserelin; D003613:Danazol